2/2 Drug Development and Capacity Building: A UCR/CoH-CCC Partnership (Education Core)

摘要： 加州大学河滨分校(UCR)是加州大学系统中最新的医学院 以及美国国立卫生研究院指定的ISUPS机构。UCR的使命是服务于SoCal的少数族裔社区 并培养下一代拉丁裔/拉美裔美国人和黑人/非裔美国人的工程师、生物学家、 还有医生。希望之城综合癌症中心(CoH-CCC)是一个综合性癌症中心 其121名研究人员已获得超过7500万美元的NIH/NCI资金。COH-CCC在全球领先 学术药物发现，并已将HumalinTM、HerceptinTM等重磅炸弹药物商业化 利妥昔单抗TM.COH拥有世界级的药物设计生物信息学、广泛的筛选和合成能力， 三个现场GMP生产设施，以及一个强大的临床/翻译第一阶段计划。在过去5年中 21年来，药物已经从R01概念试验变成了第一次人体试验。 合作癌症研究教育计划(C-REP)的目标是针对UCR和CoH-CCC 发展所需的研究经验、课程和外展教育资源 反映南加州内陆种族多样性的下一代治疗学研究人员。目标 1：研究经验将提供癌症研究和药物方面的量身定制的研究经验 发展。目标2：课程开发将提供介绍UCR和CoH学生的课程 并致力于药物开发和差异健康科学的方法和创新。目标3 外展教育和资源将使早期调查人员接触毒品的职业机会 开发和临床试验；2)为研究员和教职员工提供翻译培训和能力建设 他们的发现推动了药物发现。

Abstract: University of California at Riverside (UCR) is the newest medical school in the University of California system and a NIH-designated ISUPS institution. UCR's mandate is to serve SoCal's majority-minority communities and train the next generation of Latino/Hispanic-American and Black/African-American engineers, biologists, and physicians. City of Hope Comprehensive Cancer Center (CoH-CCC) is a Comprehensive Cancer Center whose 121 researchers have been awarded over $75M in NIH/NCI funding. CoH-CCC leads the world in academic drug discovery and has commercialized blockbusters drugs such as HumalinTM, HerceptinTM, and RituximabTM. CoH has world-class bioinformatics for drug design, extensive screening and synthetic capability, three onsite GMP-manufacturing facilities, and a robust clinical/translation Phase I program. Over the past 5 years 21 drugs have gone from R01 concept to first-in-man testing. The goal of the Collaborative Cancer Research Education Program (C-REP) is for UCR and CoH-CCC to develop the research experiences, curriculum, and outreach education resources necessary to develop the next generation of therapeutics researchers that reflect the ethnic diversity of Inland Southern California. Aim 1: Research Experiences will provide tailored research experiences in cancer research and drug development. Aim 2: Curriculum Development will provide courses to introduce both UCR and CoH students and faculty to methods and innovation in drug development and the health science of disparities. Aim 3 Outreach Education and Resources will 1) expose early stage investigators to career opportunities drug development and clinical trials and 2) provide training and capacity building for fellows and faculty to translate their findings to drive drug discovery.